P3, N=1370, Recruiting, Celldex Therapeutics | Not yet recruiting --> Recruiting

P2, N=160, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

Interventions utilizing a range of inhibitors at the in vitro level, including the PDGFR-β inhibitor AG1296, the PI3K inhibitor LY294002, the AKT inhibitor MK2206, and the FAK inhibitor Y15, demonstrated that E. multilocularis protoscoleces protein (EmP) induces angiogenesis through PDGFR/PI3K/AKT/FAK signaling pathway. Our findings provide new perspectives on how E. multilocularis infection triggers pathological angiogenesis in the host liver, and may provide a novel anti-angiogenic therapeutic strategy against E. multilocularis infection.

In light of the lack of metastatic dissemination and the patient's advanced age, targeted therapy with imatinib was commenced, leading to the elimination of hypoglycemia episodes. This case underscores the necessity of incorporating NICTH into the differential diagnosis of hypoglycemia in non-diabetic individuals, particularly when a tumor is present. Timely identification and focused intervention of the underlying neoplasm can result in positive outcomes.

This study describes a novel mechanism of direct bone marrow-mediated protection of leukemic cells from imatinib/TKI, related to transfer of metabolic proteins leading to higher activity of TCA cycle, metabolic plasticity and adaptation. Targeting the stroma-driven TCA cycle-related metabolism combined with imatinib presents a promising strategy to achieve therapeutic efficacy to overcome bone marrow microenvironment-mediated protection in CML.

P2, N=50, Active, not recruiting, Universität des Saarlandes | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Jan 2026

P3, N=1370, Not yet recruiting, Celldex Therapeutics

P2, N=30, Not yet recruiting, Fudan University

These models have the potential to guide clinicians' treatment decisions and provide prognostic evaluations. Future prospective studies with larger cohorts, as well as integration of imaging biomarkers are warranted to optimize these predictive models.

Subsequently, multiple hepatic metastases and pelvic dissemination developed, and conventional chemotherapy including bevacizumab was ineffective...Switching to sorafenib led to further progression, but reintroduction of LVB reduced Tg levels...The patient has survived seven years since recurrence, including six years on LVB. The tumor behaved similarly to poorly differentiated thyroid carcinoma, with Tg levels reflecting disease activity and LVB demonstrating the potential for long-term tumor control.

Thus, our findings uncover a novel ERK-mTOR-axis for upregulation of proteasomal degradation of XIAP which could be targeted to overcome Imatinib-resistance by combinatorial inhibition of mTOR and XIAP in CML. This study holds the promise of a new therapeutic strategy for overcoming drug resistance in cancer.